A Prospective, Randomized, Subject- and Examiner-Masked, Multicenter Study Comparing Bilateral Clareon TruPlus and Bilateral Clareon Monofocal Intraocular Lens Implantation (Spherical and Toric) in Cataract Subjects

NCT07693205 | Recruiting Phase 4 FDA Device

• 1 other identifier: 102811821
• Study Type: interventional
• Target: 180
• Locations: 1 country
• Sites: 1

Brief Summary

This investigator-initiated trial is a prospective, randomized, parallel-group, bilateral implantation study comparing Clareon TruPlus versus Clareon monofocal intraocular lenses (IOLs). Spherical and toric models are permitted in both arms based on standardized preoperative planning and clinical indication. Subjects and postoperative examiners/technicians will be masked to IOL assignment; surgeons will not be masked. The overall structure is modeled after randomized bilateral implantation cataract study designs with a Month 3 primary endpoint visit.

Conditions

Cataract

Outcome Measures

Primary Outcomes (1)

• Binocular photopic corrected distance visual acuity (CDVA) at 4 m

  3 months postoperatively

Other Outcomes (15)

• Binocular photopic distance corrected intermediate visual acuity (DCIVA) at 66 cm

  3 months postoperatively

• Binocular photopic distance corrected near visual acuity (DCNVA) at 40 cm

  3 months postoperatively

• Binocular mesopic corrected distance visual acuity (CDVA) at 4 m

  3 months postoperatively

Study Arms (2)

Clareon TruPlus

EXPERIMENTAL

Device: Clareon TruPlus

Clareon monofocal

ACTIVE COMPARATOR

Device: Clareon monofocal

Interventions

Clareon TruPlus DEVICE

Bilateral implantation with Clareon TruPlus

Clareon TruPlus

Clareon monofocal DEVICE

Bilateral implantation with Clareon monofocal

Clareon monofocal

Eligibility Criteria

• Age: 22 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adult cataract patients aged ≥22 years scheduled for cataract surgery in both eyes due to visually significant cataracts.
• Ability to understand and sign an IRB/ethics committee-approved informed consent form.
• Willingness and ability to attend all scheduled study visits as required by the protocol and complete all study testing procedures.
• Postoperative potential visual acuity of 20/25 or better in each eye, as determined by the investigator.
• Preoperative corneal astigmatism that can be corrected with a T3-T5 toric IOL, or with a spherical IOL plus LRIs/Aks, with either resulting in a predicted postoperative astigmatism \<0.50 D.
• IOL power and, if toric, cylinder availability within labeled ranges for the assigned IOL family.
• Ability to understand and complete study questionnaires.

You may not qualify if:

• Women who are pregnant, planning to become pregnant during the study period, or breastfeeding (by verbal confirmation).
• Ocular conditions that could confound study results, including moderate-to-severe corneal pathology, irregular astigmatism, moderate-to-severe dry eye/ocular surface disease not optimized, preexisting retinal degenerative disease (e.g., age-related macular degeneration), diabetic retinopathy, or other clinically significant retinal pathology.
• Any form of confirmed glaucomatous optic neuropathy or other optic nerve disease expected to affect visual function outcomes.
• History of amblyopia, monofixation syndrome, or other binocular vision disorder with poor stereopsis that could confound binocular testing.
• Prior ocular surgery (including corneal refractive surgery) in either eye.
• Zonular laxity/dehiscence, pseudoexfoliation with clinically significant zonulopathy, nystagmus, or strabismus that could compromise uncomplicated surgery or reliable visual testing.
• Participation in another clinical study (interventional) that could interfere with study results.
• Planned monovision/mini-monovision or desire for monovision targeting.
• Systemic conditions that may affect healing or visual outcomes (e.g., uncontrolled diabetes mellitus, certain autoimmune disorders) per investigator judgment.
• Psychiatric or cognitive disorders that may impair the ability to comply with study procedures or provide reliable self-assessments.
• Any active ocular infection or inflammation.

Sponsors & Collaborators

• Berkeley Eye Center: lead
• Sengi: collaborator

Study Sites (1)

Berkeley Eye Center - Sugar Land

Sugar Land, Texas, 77478, United States

RECRUITING

MeSH Terms

Conditions

Cataract

Condition Hierarchy (Ancestors)

Lens Diseases; Eye Diseases

Central Study Contacts

Tetiana Huff

CONTACT

713-620-7640; tetiana.huff@berkeleyeye.com

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 3, 2026
• First Posted: July 9, 2026
• Study Start: June 12, 2026
• Primary Completion (Estimated): July 1, 2027
• Study Completion (Estimated): July 1, 2027
• Last Updated: July 21, 2026

Record last verified: 2026-07

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)